About Acorda Therapeutics
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States. In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301. In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.